Methods: A prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group study was performed in older patients (Ն60 years) with systolic blood pressure (SBP) Ͼ140 mg, diastolic blood pressure (DBP) Յ95 mmHg, and 24-h mean ambulatory SBP Ͼ125 mmHg. After a 2-to 4-week placebo run-in, patients were randomized to treatment with telmisartan (T) 40 mg for 2 weeks, with uptitration to T 80 mg for 6 weeks and then to T 80 mg ϩ hydrochlorothiazide (H) 12.5 mg for 6 weeks or amlodipine (A) 5 mg, with uptitration to A 10 mg for 6 weeks and then to A 10 mg ϩ H 12.5 mg for 6 weeks. Efficacy was determined using 24-h ambulatory blood pressure monitoring. Adverse events (AEs) were monitored.
P-237 MP-29 COMBINATION OF TOPROL-XL AND HYDROCHLOROTHIAZIDE: RESULTS OF A FACTORIAL CLINICAL TRIAL
Vasilios Papademetriou, James W Hainer, Jennifer Sugg, ATTACH Investigators. Hypertension Research, VA Medical Center and Georgetown University Medical Center, Washington, DC; Clinical Research, AstraZeneca, Wilmington, DE; Quantatative Decision Sciences, AstraZeneca, Wilmington, DE. Most hypertensive patients require 2 or more drugs to achieve target blood pressure. Results of the ALLHAT trial indicate that diuretic-based antihypertensive regimens are effective in reducing cardiovascular morbidity and mortality.
The ATTACH trial evaluated 3 dose levels of hydrochlorothiazide (HCT) (6.25 mg, 12.5 mg and 25 mg), 4 levels of metoprolol succinate extended release (Toprol-XL) (25 mg, 50 mg, 100 mg and 200 mg), 9 of the possible combinations and placebo in an 8 week, multicenter, randomized, double-blind unbalanced factorial trial in patients with essential hypertension (DBP Ͼ 95, Ͻ 114 mm Hg; SBPϽ180 mm Hg).
The investigators randomized 1571 patients; 51% were male, 16% were Ͼ 65 years of age and 25% were black. Mean baseline blood pressure was 151/100 mm Hg.
Blood pressure declined significantly relative to placebo (pϽ0.05) with all combinations (placebo-subtracted range SBP/DBPϭ 6.1/3.9 to 15.9/12.2 mm Hg) ( Figure) . Each component contributed to the effect of the combination for both DBP (T-AVE p ϭ 0.0015) and SBP (T-AVE pϭ0.0006).
Forty-six (2.9%) patients discontinued for adverse events but there was no clustering of events in any one treatment group. Serum potassium declined with HCT and was related to dose.
Toprol-XL-HCT is an effective antihypertensive combination agent over the range of doses (HCT 6.25 Background: Modulation of the autonomic nervous system through an increase in heart rate variability (HRV) with potential benefits in reducing the risk of ventricular arrhythmias has been demonstrated earlier in ischaemic heart disease with drugs affecting the renin-angiotensin system. The VALUE-trial explored the possible cardiac benefits of a valsartan-based (VAL) regimen compared to treatment with amlodipine (AML) in high-risk hypertensive patients. The purpose of the present substudy was to evaluate the treatment effects on the ECG and HRV calculated from ambulatory electrocardiographic recordings obtained by Holter technique during 24 hours.
Methods: Nine Danish VALUE-centres with a total of 148 patients participated in this substudy. Holter-recordings (2-channel Tracker, Reynolds Pathfinder analysis) were obtained after two years of maintained randomized therapy. From Holter data ventricular arrhythmias were classified according to severity and from 2-hours periods during day and night, time domain HRV measures were derived.
Results: The demographics showed two well-balanced groups with equal blood pressure reduction to 140/80 mmHg. Potassium levels were equal (VAL 4.1 Ϯ0.4 vs. 3.9 Ϯ0.4 mmol/L, ns). Beta-blockers were given as add-on to 37% in both groups. After 2 years the measured ECG criteria for left ventricular hypertrophy and the levels of QTc (VAL 406 Ϯ25 vs. 413 Ϯ27 msec, ns) and QT-dispersion (VAL 35 Ϯ17 vs. 38 Ϯ15 msec, ns) were equal.in the two groups. The long term HRV measured as the standard deviation of the average normal to normal intervals (SDANN) was significantly higher in VAL compared with AML during the night (38 Ϯ17 vs. 32 Ϯ13 msec, Pϭ0.019), whereas the SDANN did not differ between the two groups in the daytime. The 24 hour triangular index was significantly higher in VAL compared with AML (32 Ϯ11 vs. 28 Ϯ9, Pϭ0.02). The prevalence of all categories of ventricular arrhythmia as well as the prevalence of atrial fibrillation was equal in the two groups.
Conclusion: Two indices of long-term HRV showed differences in favour of the VAL regimen. Although baseline HRV data were not obtained, the findings in this study substantiate correlation between a treatment regimen based on valsartan and alteration of the autonomic cardiovascular control through an increase of HRV.
